Allogene Therapeutics, Inc. (ALLO) SEC Filings & Earnings Calls

Major insider exit risk

“As a result of the September 2026 Offering, the Reporting Persons no longer beneficially own any shares of Common Stock.” · word for word

Key financial officer departure without named successor may disrupt financial planning and investor confidence.

“CFO retirement effective Nov 6, 2026; no successor identified.”

Clinical-stage biotech with no approved products; reliance on trial outcomes and regulatory approvals.

“Clinical-stage biotechnology company; no revenue; ALPHA3 enrollment completion expected year-end 2027.”

Need for Additional Capital

“Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.” · word for word

License Termination Risk (Cellectis/LTC)

“In April 2026, the Company received correspondence from Life Technologies Corporation (LTC), a subsidiary of Thermo Fisher Scientific, asserting that Cellectis had sublicensed to the Company or otherwise made available rights under certain patents licensed by LTC to Cellectis relating to TALEN technology, and that LTC had terminated its license agreements wi” · word for word

CIRM Award Repayment Risk

“The maximum royalty that the Company may be required to pay to CIRM is equal to nine times the total amount awarded and paid to the Company.” · word for word

Potential dilution from equity offering and increased authorized shares could pressure existing shareholders.

“Up to $135M in common stock sales under ATM; authorized shares doubled to 800M.”

CEO transition may introduce strategic uncertainty, though internal succession mitigates disruption risk.

“Founder/CEO David Chang stepping down; new CEO is internal with R&D background.”

Termination of license agreement reduces potential future milestone and royalty revenue from Asian markets.

“License Agreement terminated; Allogene surrendered equity; no termination payments.”

Clinical trial risk: ALPHA3 interim EFS analysis not expected until mid-2027; ALLO-329 still in early dose escalation.

“Interim EFS analysis expected mid-2027; ALLO-329 at dose levels 1 and 2.”

Need for additional capital

“Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.” · word for word

TALEN technology rights risk

“In April 2026, the Company received correspondence from Life Technologies Corporation (LTC)... asserting that Cellectis had sublicensed to the Company or otherwise made available rights under certain patents licensed by LTC to Cellectis relating to TALEN technology, and that LTC had terminated its license agreements with Cellectis.” · word for word

Overland Therapeutics termination

“On May 12, 2026, the Company entered into a termination agreement with Overland Therapeutics (SH) Co. Ltd. and Overland Therapeutics Inc., pursuant to which the License Agreement was terminated in its entirety.” · word for word

Need for additional capital (authorized share increase)

“To approve an amendment to our Certificate of Incorporation to increase the number of authorized shares of common stock from 400,000,000 shares to 800,000,000 shares.” · word for word

Executive Chair compensation scrutiny

“The Board recognizes that some stockholders and proxy advisors have raised questions about the absolute level of Executive Chair pay at companies where the chair performs expanded operational and strategic duties.” · word for word

Director non-compliance with stock ownership guidelines

“One director was not in compliance as of December 31, 2025 based on the calculation required under the policy, which utilizes the average stock price over the 90 trading days prior to such date.” · word for word

Significant dilution from large equity offering at low price; potential for further dilution if underwriters exercise option.

“issuance and sale in a public offering of 87,500,000 shares of our common stock, par value $0.001 per share. The price to the public in the offering is $2.00 per share” · word for word

Suspension of ATM program indicates shift to larger equity offering, potentially more dilutive.

“the Company has suspended the offering of any shares of its common stock pursuant to the sales agreement prospectus” · word for word

Small sample size (24 patients) limits statistical power; interim analysis may not predict final outcomes.

“This interim futility analysis was based on the first 24 patients randomized” · word for word

Trial still enrolling; primary EFS analysis not expected until mid-2028; regulatory approval uncertain.

“Study accrual is anticipated to be complete by the end of 2027. The Company anticipates an interim EFS analysis in mid-2027 and the primary EFS analysis in mid-2028” · word for word

Novel technology risk

“Our product candidates are based on novel technologies, which makes it difficult to predict the time and cost of product candidate development and the likelihood of obtaining regulatory approval.” · word for word

Clinical trial safety risk (Grade 5 SAE)

“Following a Grade 5 treatment-related serious adverse event observed in the FCA arm, in August 2025 we announced the discontinuation of dosing in the FCA arm, and we terminated further development of ALLO-647.” · word for word

Need for additional financing

“We will need substantial additional financing to develop our products and implement our operating plans.” · word for word

Competition from autologous CAR T and other therapies

“We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.” · word for word

Manufacturing and supply chain risk

“We may fail to successfully manufacture our product candidates, operate our own manufacturing facility, or obtain regulatory approval to utilize or commercialize from our manufacturing facility or at a CDMO” · word for word

Clinical-stage company with no approved products; pipeline dependency on trial results.

“No revenue reported; cash runway extended but no product revenue.”

Clinical-stage biotech with no approved products; significant reliance on pipeline success.

“Pre-revenue; net loss $41.4M; cash burn guidance ~$150M for 2025.”

Clinical trial failure risk

“we have terminated the FCA arm of the ALPHA3 trial... Additionally, we have terminated all further development of ALLO-647.” · word for word

Financing risk

“We will need substantial additional financing to develop our products and implement our operating plans.” · word for word

Regulatory risk

“The FDA placed our clinical trials on hold in October 2021, which suspended our clinical programs prior to resolution of the hold in January 2022.”